Abstract
The results of 2 separate studies presented at the 32nd Annual Meeting of the American Society of Clinical Oncology (ASCO) [ Philadelphia, Pennsylvania; May 1996 ] have indicated that newly developed thrombopoietic agents are capable of reducing chemotherapy-induced thrombocytopenia in patients with cancer. The agents involved in the trials were recombinant human thrombopoietin [rhTPO; Genentech; phase I] and pegylated recombinant human megakaryocyte growth and development factor [MGDF; Amgen; phase I/II]. According to the researchers, the addition of these agents to chemotherapy regimens led to a more rapid restoration of platelet levels to baseline and permitted the administration of larger doses of chemotherapy, compared with chemotherapy alone.
Rights and permissions
About this article
Cite this article
Prescott, L. Long-awaited clinical data for platelet factors. Inpharma Wkly. 1044, 9–10 (1996). https://doi.org/10.2165/00128413-199610440-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-199610440-00018